What is the price target for TCRR stock?
12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.
TCR2 THERAPEUTICS INC (TCRR) Forecast, Price Target & Analyst Ratings
NASDAQ:TCRR • US87808K1060
Current stock price
1.48 USD
-0.09 (-5.73%)
At close:
1.53 USD
+0.05 (+3.38%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TCR2 THERAPEUTICS INC (TCRR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 7, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$0.65
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.86
Upside
+ 295.87%
From current price of $1.48 to mean target of $5.86, Based on 12 analyst forecasts
Low
$1.74
Median
$2.04
High
$21.00
Price Target Revisions
1 Month
13.37%
3 Months
-41.98%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for TCRR. The average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.
The average price target has been revised downward by 41.98% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
73.33%
TCRR was analyzed by 12 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about TCRR.
In the previous month the buy percentage consensus was at a similar level.
TCRR was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-03-24 | Mizuho | Downgrade | Buy -> Neutral |
| 2023-03-23 | EF Hutton | Reiterate | Hold |
| 2023-03-09 | Jefferies | Downgrade | Buy -> Underperform |
| 2023-03-08 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-03-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-01-06 | Piper Sandler | Maintains | Overweight |
| 2023-01-05 | EF Hutton | Initiate | Hold |
| 2022-11-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-05-19 | HC Wainwright & Co. | Maintains | Buy |
| 2022-01-19 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-01-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-10 | SVB Leerink | Maintains | Market Perform |
| 2021-10-21 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-09-20 | Truist Securities | Maintains | Buy |
| 2021-09-20 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-06 | SVB Leerink | Maintains | Outperform |
| 2021-06-24 | Goldman Sachs | Initiate | Buy |
| 2021-03-11 | SVB Leerink | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 7, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$0.65
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 21.22%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-34.75%
EPS (3 Months)
0.13%
Next Earnings Summary
TCRR is expected to report earnings on 8/7/2023. The consensus EPS estimate for the next earnings is -0.65 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 457.34% | N/A 365.49% | N/A 81.55% | N/A 32.85% | N/A -12.72% | ||||||||
| EBITDA YoY % growth | -9.71M | -12.88M -32.65% | -26.03M -102.10% | -50.52M -94.08% | -67.11M -32.84% | -93.254M -38.96% | -119.808M -28.47% | N/A -51.05% | N/A -18.60% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -9.93M | -13.18M -32.73% | -26.45M -100.68% | -51.38M -94.25% | -68.7M -33.71% | -96.081M -39.86% | -122.854M -27.87% | N/A -4.33% | N/A -18.99% | N/A -10.88% | N/A 5.08% | N/A 44.66% | N/A 109.51% | N/A 802.69% | N/A 19.69% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -6.43 -13.18% | -2.43 62.21% | -2.63 -8.23% | -3.93 -49.43% | N/A 42.95% | N/A 25.27% | N/A 7.76% | N/A 53.80% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.65 21.22% | -0.46 42.33% | -0.42 73.19% |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -35.088M -10.34% | -35.649M -14.62% | -35.833M -15.57% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.13%
EPS Next 5 Year
16.12%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TCR2 THERAPEUTICS INC / TCRR Forecast FAQ
When does TCR2 THERAPEUTICS INC (TCRR) report earnings?
TCR2 THERAPEUTICS INC (TCRR) will report earnings on 2023-08-07, before the market open.
What are the consensus estimates for TCRR stock next earnings?
The consensus EPS estimate for the next earnings of TCR2 THERAPEUTICS INC (TCRR) is -0.65 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for TCR2 THERAPEUTICS INC (TCRR) stock?
The consensus rating for TCR2 THERAPEUTICS INC (TCRR) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.